SYS6043, a Subsidiary of CSPC Innovation, Initiates Phase III Clinical Trial

Baili Tianheng announced on October 11 that the company recently received the official approval of the Drug Clinical Trial Approval Notice from the National Medical Products Administration. Its self-developed, first-in-class drug Izabren (luncombe izabren, BL-B01D1/iza-bren) combined with radiotherapy for the treatment of locally advanced unresectable head and neck squamous cell carcinoma and other solid tumors has been approved for clinical trials. The announcement stated that Izabren is the world's first and only approved EGFR×HER3 bispecific antibody-drug conjugate, and has currently initiated more than 45 clinical trials for multiple tumor types in China and the United States, including 20 Phase III clinical studies (including Phase II/III). Izabren has 9 indications included in the National Medical Products Administration's Center for Drug Evaluation breakthrough therapy designation list, 2 indications included in the priority review designation list, and some indications have also received marketing approval from the National Medical Products Administration. In mid-2026, Baili Tianheng achieved revenue of 0.0 yuan and a net loss attributable to the parent company of 1.637 billion yuan.

AbbVie received two FDA Breakthrough Therapy Designations for its experimental cancer drug telisotuzumab adizutecan in colorectal cancer and non small cell lung cancer. The designations apply to biomarker defined patient groups in those two large solid tumor indications, and they mark the first Breakthrough Therapy status for telisotuzumab adizutecan, which sits in AbbVie's antibody drug conjugate pipeline. Colorectal cancer and non small cell lung cancer together affect more than four million people worldwide each year, and the focus on biomarker defined groups, including c Met protein expressing NSCLC, points to narrower patient pools but potentially higher value treatment settings. The designations support the view that AbbVie needs its pipeline to replace aging blockbusters such as Humira and Imbruvica, with telisotuzumab adizutecan complementing oncology assets like etentamig. The next signpost is how the ongoing Phase 3 and Phase 2/3 telisotuzumab adizutecan studies progress and when AbbVie moves toward regulatory filings in colorectal cancer and non small cell lung cancer, building on the first in human M21 404 data.

MicuRx Pharmaceuticals announced that it plans to sign an exclusive license agreement for the MRX-23 program and a platform technology collaboration agreement with ClearideBio of Switzerland. The former involves a worldwide exclusive license for the MRX-23 program; the latter is a multi-program option collaboration based on the company's independently developed STOPIN antibody-drug conjugate platform with a novel camptothecin payload, under which ClearideBio may exercise options for an agreed number of targets or target combinations in accordance with the agreement. Under the MRX-23 license agreement, an upfront payment of 1 million US dollars will be paid as agreed after the agreement takes effect, and this payment is non-refundable once made. Near-term development milestone payments are triggered by the first approval of a clinical trial application for the licensed product. The nominal cap on research, registration, and sales milestone payments for MRX-23 totals 223 million US dollars; when all options under the platform collaboration are exercised and all milestones are achieved, the total payment cap is 750 million US dollars.

Pfizer is expected to report higher oncology sales in the third quarter of 2026, driven by key drugs Padcev, Lorbrena and the Braftovi-Mektovi combination, which should offset declining sales of Ibrance and Adcetris. Oncology comprises around 27% of Pfizer's total revenues, and in the second quarter of 2026 oncology revenues increased 3% to $4.17 billion, with 2% operational growth. The Zacks Consensus Estimate for Padcev is $692 million, while that for Ibrance is $1.01 billion. Pfizer, which markets six cancer biosimilars, is also expected to provide updates on key oncology candidates on its third-quarter conference call, including atirmociclib, sasanlimab and sigvotatug vedotin, as well as PF-08634404, a dual PD-1/VEGF inhibitor in-licensed from Chinese biotech 3SBio in 2025 for which Pfizer has initiated nine studies, including two pivotal phase III trials. Pfizer will announce its third-quarter results on Nov. 3.

InnoCare Pharma announced a research collaboration and license agreement with Eli Lilly to pursue up to five drug targets addressing critical unmet medical needs. The deal headlines arrive after a weaker patch for the company's shares, with the 7 day share price return down 8.65% and the 30 day share price return down 8.72%, though the year to date share price return is 8.08% and the 3 year total shareholder return is 119.32%. Against InnoCare Pharma's last close of HK$13.51, the most followed narrative anchors fair value at HK$19.62, framing the shares as 31% undervalued under a 7.25% discount rate. The company's pipeline includes late-stage drugs tafasitamab and zurletrectinib, and it is introducing an ADC platform intended to open new revenue streams. Still, the story leans heavily on a few key drugs and rising R&D spending, and the current P/E of 21.4x sits above a fair ratio of 9.8x but below a Hong Kong biotech average of 18.4x.

Biohaven Ltd. announced a clinical supply agreement with Regeneron Pharmaceuticals in September 2026 to test BHV-1530 in combination with cemiplimab, sold as Libtayo, in patients with solid tumors. The BHV-1530 collaboration follows earlier monotherapy and preclinical data suggesting potential synergy with Anti-PD-1 therapy, and it builds on an existing supply agreement covering Biohaven's next-generation TROP2-directed ADC BHV-1510, deepening Regeneron's involvement across Biohaven's oncology pipeline. The company has no revenue yet, carries very large ongoing losses, and depends on future trial readouts and capital markets rather than cash flow. Near-term swing factors include upcoming data from opakalim in focal epilepsy, the MoDE autoimmune programs, and obesity results from taldefgrobep, with regulatory progress on troriluzole also in focus. Investors in the Simply Wall St Community hold only two fair value views on Biohaven, spanning from about US$21 to nearly US$70 per share.